Background/Aims: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder with mutations in PKD1 or PKD2. This study aimed to identify novel PKD1 and PKD2 mutations in Chinese patients with ADPKD. Methods: Mutational analyses of both PKD genes were performed in 120 Chinese families with inherited ADPKD using long-range PCR and targeted next-generation sequencing approaches. Sanger sequencing was performed to check the positive mutations, while multiplex ligationdependent probe amplification was adopted to examine those without mutations for the presence of large deletions. Results: A total of 93 mutations in PKD1 and PKD2 were identified in 98 Chinese families with ADPKD inheritance and the detection rate was 81.7% (98/120). The mutation rates of PKD1 and PKD2 were 91.4% (85/93) and 8.6% (85/93), respectively. Among the 93 mutations, 59.1% (55/93) were reported for the first time. A total of 65 mutations (26 nonsense, 33 frameshift, 2 large deletion, and 4 typical splicing mutations) were identified as definite pathogenic mutations. The remaining 28 mutations (21 missense, 3 in-frame deletion, and 4 atypical splicing mutations) were determined as probable pathogenic mutations. In addition, 9 de novo mutations were found by pedigree analysis. Correlation analysis between genotype and phenotype revealed that patients with PKD1 mutations or truncating mutations exhibited the most severe clinical outcome. Conclusion: The newly identified sites for known mutations will facilitate the early diagnosis and prediction of prognosis in patients with ADPKD, and provide fundamental genetic information for clinical intervention to prevent the inheritance of this disease in affected families.
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder with an incidence ranging between 1/400 and 1/1000 [1] . It is a chronic progressive disease characterized by gradually enlarging renal cysts in bilateral kidneys and contributes to approximately 10% of end stage renal disease (ESRD) [2] .
ADPKD is a systemic disease that involves different organs [1] [2] [3] [4] . However, all ADPKD phenotypes are caused by mutations in 2 genes, PKD1 (16p13.3) [5] and PKD2 (4q21) [6] , which encode polycystin-1 (PC1) and polycystin-2 (PC2), respectively. Mutations in PKD1 (85% of all cases) have closer associations with a severe clinical presentation and poorer prognosis than those in PKD2 (15% of all cases), which suggests a critical role for these genetic factors in predicting the outcomes of patients with ADPKD [7, 8] .
At present, the clinical diagnosis of ADPKD is mainly based on renal imaging techniques using the age-related cyst number criteria [9, 10] . However, it is a considerable challenge to provide a definite diagnosis using the current criteria for younger patients without a positive family history or those with PKD2 mutations. Meanwhile, effective treatment options for this inherited disease are far from sufficient [2] . Recently, we report that blocking gene inheritance through preimplantation genetic diagnosis is the most effective way to reduce the incidence of ADPKD [11] . Therefore, comprehensive mutational information of both PKD genes is the key to the early diagnosis of ADPKD and early genetic intervention.
PKD1 consists of 46 exons with a coding sequence of 12912 bp. PKD2 is composed of 15 exons with a coding sequence of 2907 bp [12] . Both gene sequences are highly variable [13] . To date, a total of 1273 pathogenic PKD1 and 202 pathogenic PKD2 mutations have been reported in the Polycystic Kidney Disease Mutation Database (PKDB; http://pkdb. mayo.edu/). However, most mutations are unique as a single-family entity and recurrent mutations account for only 30% of all identified mutations [8] . Thus, it is necessary to investigate a larger number of affected family pedigrees to confirm these known mutations, particularly for missense, in-frame deletion, and atypical splicing mutations. Additionally, most of the currently known mutations listed in PKDB were acquired from studies of Caucasian populations. Mutational data from Asian populations are essential to broaden the representativeness of the database. In the present study, we directly screened PKD1 and PKD2 in a total of 120 Chinese families to identify novel mutations that contribute to the development of ADPKD.
Materials and Methods

Patients
Patients who were diagnosed with ADPKD at the Department of Nephrology of the Kidney Institute of the People's Liberation Army, Changzheng Hospital, Second Military Medical University, from January 2016 to August 2017, were enrolled in this study. Diagnostic criteria for ADPKD based on renal ultrasound analysis were adopted as described previously [9, 14] . All enrolled patients provided informed consent and blood samples were obtained from 120 families including at least 1 affected individual. The study was approved by the Ethics Committee of Changzheng Hospital.
Long-range PCR (LR-PCR) amplification, targeted next-generation sequencing, and mutation identification
Approximately 5 mL peripheral blood was obtained from each enrolled individual, and genomic DNA was extracted from lymphocytes by using a DNA extraction kit (QIAamp DNA Blood Mini Kit; QIAGEN, Inc., Valencia, CA). The exons, most of the 5′ and 3′ untranslated regions (UTRs), and the exon-intron boundaries of PKD1 and PKD2 were amplified with a total of 6 distinct LR-PCR reactions (5 reactions for PKD1 and 1 reaction for PKD2). The LR-PCR primers chosen for PKD1 and PKD2, LR-PCR amplification reaction system, and amplification conditions for the various LR-PCR fragments have been described elsewhere [11] . The LR-PCR products for PKD1 and PKD2 were purified with Agencourt AMPure XP Beads, followed by quantification and fragmentation using a NEBNext Fast DNA Fragmentation Kit (New England BioLabs, Ipswich, MA). A sequencing library of the LR-PCR products and other Ampliseq multiplex PCR products was constructed with an Ion Plus Fragment Library Kit (Thermo Fisher Scientific, Waltham, MA) and then sequenced with an Ion PGM™ 200 Sequencing Kit (Thermo Fisher Scientific). Mutations identified in PKD1 and PKD2 were validated by Sanger sequencing. Patients who had no mutations in PKD1 and PKD2 were screened for large deletions by multiplex ligation-dependent probe amplification (MLPA) analysis [15, 16] . All sequencing reads were mapped to the PKD1/2 reference genome (NM_001009944.2 for PKD1 and NM_000297.2 for PKD2) with Torrent Server TMAP software. The standard nomenclature recommended by HGVS (http://www.hgvs.org/mutnomen/) was adopted to name the mutations identified in this study. The dbSNP138, 1000 Genomes, Exon Sequencing Project (http://evs.gs.washington.edu), HapMap, and PVFD (variant frequency in normal populations) databases were used to filter out polymorphic variants. In accordance with the Human Gene Mutation Database (http://www.hgmd.cf.ac.uk) and PKDB, the remaining mutations were divided into known mutations and novel mutations.
Evaluation of the pathogenicity of sequencing mutations
Nonsense, frameshift, typical splicing, and larger deletion mutations were defined as definite pathogenic mutations; while missense, atypical splicing, and in-frame deletion mutations were considered probable pathogenic mutations in this study [17] .
For the known probable pathogenic mutations, we firstly screened PKDB to determine if their pathogenicity was known (highly likely pathogenic or likely pathogenic). Secondly, we used several web-based prediction tools to evaluate the pathogenic potential of these mutations: The PolyPhen-2 (Polymorphism Phenotyping v2; http://genetics.bwh.harvard.edu/pph/) [18] and Sorting Intolerant from Tolerant (SIFT) (http://sift.jcvi.org/) [19] tools were used for missense mutations, and the Mutation Taster (http://mutationtaster.org/) tool [20] was used for missense and in-frame deletion mutations. The PolyPhen-2 tool could divide the mutations into 3 categories (benign, possibly damaging, and probably damaging); the SIFT tool could divide the mutations into 2 categories (tolerated and damaging); and the Mutation Taster could divide the mutations into 2 categories (polymorphism and disease-causing). Finally, segregation analyses were performed by direct sequencing of parental DNA to verify the pathogenicity of those mutations in the pedigree.
For novel probable pathogenic mutations, the PolyPhen-2, SIFT, and Mutation Taster tools were also used to evaluate their potential pathogenicity, and segregation analysis was further performed to verify their pathogenicity in the pedigree.
Mutation domain analysis
Several domain databases were used to analyze the mutation domains of PC1 and PC2, including the Simple Modular Architecture Research Tool (http://smart.embl-heidelberg.de), Pfam (http://pfam.xfam. org/), and PROSITE (http://prosite.expasy.org/). The mutation domains for PC1 and PC2 were determined by the location of the initial mutation site of amino acids.
Statistical analysis
The significance of comparisons was determined by the chi-squared test using SPSS 17.0 software (SPSS, Inc., Chicago, IL). A p-value < 0.05 was considered statistically significant.
Results
General characteristics of the mutations in 120 families
A total of 120 families were enrolled in this study. Among which, 93 mutations in PKD1 and PKD2 were found in 98 families, and the remaining 22 families had neither PKD1 nor PKD2 mutations. The overall mutation rate of both PKD genes was 98/120 (81.7%). Of these 93 mutations, 55 (59.1%) were detected as novel mutations and 38 (40.9%) as known mutations.
Screening of PKD1 and PKD2 revealed 85 mutations in PKD1 (34 known mutations and 51 novel mutations) and 8 mutations in PKD2 (4 known mutations and 4 novel mutations). The mutation rates of PKD1 and PKD2 were 91.4% (85/93) and 8.6% (8/93), respectively. Among the 34 known mutations of PKD1, 15 (44.1%) were nonsense mutations, 6 (17.6%) were frameshift mutations, 1 (2.9%) was an in-frame deletion, 10 (29.4%) were missense mutations, 1 (2.9%) was a splice-site mutation, and 1 (2.9%) was a large deletion; 3 (75%) of the 4 known PKD2 mutations were nonsense mutations and 1 (25%) was a splice-site mutation. Meanwhile, 9 (17.6%) of the 51 novel PKD1 mutations were nonsense mutations, 26 (51.0%) were frameshift mutations, 2 (3.9%) were in-frame deletions, 9 (17.6%) were missense mutations, 4 (7.8%) were splice-site mutations, and 1 (2.0%) was a large deletion; 1 (25%) of the 4 novel PKD2 mutations was a nonsense mutation, 2 (50%) were missense mutations, and 1 (25%) was a splice-site mutation (Fig. 1) .
Definite pathogenic mutations
In this study, 69.9% (65/93) of the mutations were detected as definite pathogenic mutations. Of these 65 mutations, 25 (17 nonsense, 6 frameshift, and 1 large deletion) were regarded as known mutations (Table 1) , while the other 40 were considered to be novel mutations ( Table 2 ). Among the known mutations, 2 nonsense mutations (PKD1 c.6472C>T and PKD1 c.12124C>T) were found in 3 families; 1 nonsense mutation (PKD1 c.11884C>T) and 1 frameshift mutation (PKD1 c.6727_6728delCA) were found in 2 families, and the remaining 21 mutations were found in single families. Among the 40 novel mutations identified, 9 were nonsense mutations, 27 were frameshift mutations, 1 was a large deletion, and 3 were typical splicing mutations. Most of these mutations were found in single pedigrees, except for PKD1 c.10524_10525insT (found in family no. 91 and family no. 93). By using MLPA analysis, a known large deletion mutation (exon 1 of PKD1) and a novel large deletion mutation (from exon 7 to exon 15 of PKD1) were found in family no. 87 and family no. 44, respectively. The rate of large deletion mutations in PKD1 was 2.4% (2/85). Missense mutations A total of 21 missense mutations (10 known and 11 novel) were found in this study. The characteristics of the 10 known missense mutations are described in Table 3 . All 10 of the known missense mutations were in PKD1 and were defined as highly likely pathogenic or likely pathogenic mutations by PKDB. In these 10 missense mutations, 8 were identified as "probably damaging," 1 as "possibly damaging" (PKD1 c.9136C>T), and 1 as "benign" (PKD1 c.385T>C) by the PolyPhen-2 tool. Using the SIFT and Mutation Taster tools, 9 of the 10 missense mutations were demonstrated to be pathogenic mutations, except for PKD1 c.11156G>A. Pedigree analysis revealed that 5 missense mutations (PKD1 c.385T>C, PKD1 c.3722T>A, PKD1 c.6832G>A, PKD1 c.9409C>T, and PKD1 c.9412G>A) were pathogenic and co-segregated with ADPKD, while 2 missense mutations (PKD1 c.11156G>A and PKD1 c.11257C>T) were de novo mutations. Provided with incomplete pedigree information for families no. 2 and no. 46, the pathogenicity of another 2 missense mutations (PKD1 c.7483T>C and PKD1 c.9136C>T) was not determined by pedigree analysis.
The mutational characteristics of the 11 novel missense mutations are described in Table 4 . There were 9 and 2 mutations in PKD1 and PKD2, respectively. Among which, 6/9 PKD1 mutations were classified as "probably damaging," 1/9 PKD1 mutations and 2/2 PKD2 mutations were classified as "possibly damaging," and 2/9 PKD1 mutations were classified as "benign" by the PolyPhen tool. Meanwhile, 7/9 PKD1 mutations and 1/2 PKD2 mutations were classified as "damaging" by SIFT. According to the Mutation Taster tool, 7/9 PKD1 mutations and 2/2 PKD2 mutations were classified as "disease-causing." Pedigree analysis revealed that 6/9 PKD1 mutations and 2/2 PKD2 mutations were pathogenic mutations, 2/9 PKD1 mutations (c.2897G>C and c.11541C>A) were de novo mutations, and 1/9 PKD1 mutations (c.11541C>A) was indeterminate due to incomplete pedigree information for family no. 15. Two missense mutations (PKD1 c.4984G>A and PKD1 c.7544G>C), which were demonstrated to be benign by the prediction tools (more than 2/3 prediction tools suggested they were non-pathogenic), were classified as pathogenic mutations in pedigree analysis. Two PKD1 missense mutations (c.2897G>C and c.8572G>A) were found in family no. 6. The novel PKD1 missense mutation c.2897G>C at exon 12 resulted in the substitution of a basic arginine residue for a non-polar hydrophobic proline residue at position 966 (p.Arg966Pro). All 3 prediction tools identified c.2897G>C to be a pathologic mutation. Moreover, pedigree analysis revealed that c.2897G>C was a de novo mutation in family no. 6. The known PKD1 missense mutation c.8572G>A at exon 23 led to the replacement of a non-polar hydrophobic glycine residue with a polar neutral serine residue at position 2858 (p.Gly2858Ser). All 3 prediction tools and PKDB identified c.8572G>A as a pathologic mutation. However, pedigree analysis revealed that the c.8572G>A mutation in the proband was inherited from the unaffected father, which was also found in an unaffected brother, indicating that c.8572G>A was not a pathologic mutation (Fig. 2) . In-frame deletion mutations Three in-frame deletion mutations of PKD1 were found in this study (Table 5) . One of the in-frame deletion mutations (PKD1 c.7825_7827delATC) was reported previously as a pathogenic mutation within Mutation Taster and PKDB. Moreover, the pathogenicity of this mutation was verified by pedigree analysis. The remaining 2 in-frame deletion mutations were novel. One mutation (PKD1 c.8318_8326delCCCTGACGC) was demonstrated to be a pathogenic mutation by Mutation Taster and pedigree analysis, while the pathogenicity of another mutation (PKD1 c.12399_12407delCCTGCGCAG), which was demonstrated to be a polymorphism by Mutation Taster, was defined as indeterminate in pedigree analysis due to the lack of complete pedigree information.
Atypical splicing mutations
The characteristics of the 4 atypical splicing mutations are described in Table 5 . Among which, 2 mutations (PKD1 c.11017-10C>A and PKD2 c.1094+3_+6delAAGT) were reported previously and classified as highly likely pathogenic mutations by PKDB. They were also defined as pathogenic mutations by pedigree analysis. The remaining 2 mutations (PKD1 c.10822-3C>G and PKD2 c.1095-16_1095-8del9TTTCCTTTG) were novel atypical splicing mutations, which were further found to co-segregate with ADPKD in families no. 16 and no. 28 by pedigree analysis, suggesting the pathogenic nature of these atypical splicing mutations.
De novo mutations
A total of 9 de novo mutations of PKD1 were identified in this study (Table 6 ). Among which, 3 (33.3%) were frameshift mutations, 4 (44.5%) were missense mutations, 1 (11.1%) was a nonsense mutation, and 1 (11.1%) was a typical splice mutation. Two of the missense mutations (c.11257C>T and c.11156G>A) had been reported previously as pathologic mutations. The remaining 2 missense mutations (c.2897G>C and c.11541C>A), which occurred de novo in the probands, were novel mutations found in this study and demonstrated to be pathologic mutations by the prediction tools. Fig. 2 . Two mutations in family no. 6. Two mutations (PKD1 c.2897G>C and PKD1 c.8572G>A) were detected in family no. 6. The PKD1 c.2897G>C mutation was revealed as a de novo mutation; the PKD1 c.8572G>A mutation did not co-segregate with the PKD1 disease phenotype in this family.
Association between genotype and phenotype
Approximately 50% of ADPKD patients progress to ESRD before the age of 60 years. To evaluate the association between genotype and phenotype, we analyzed the rate of ESRD before 60 years of age in the available pedigrees. A total of 73 pedigrees were enrolled with 67 mutations in PKD1 and 6 mutations in PKD2. Of these pedigrees, 42/73 (57.5%, involving 41 PKD1 mutations and 1 PKD2 mutation) had individuals who developed ESRD before 60 years of age. The ESRD rate for the PKD1 mutations (41/67, 61.7%) was significantly higher than that of the PKD2 mutations (1/6, 16.6%) (p = 0.035). A total of 49 truncating mutations and 18 non-truncating mutations were found in the 67 PKD1 mutational pedigrees. Of these mutations, 34/49 (69.4%) truncating mutations (14 nonsense and 20 frameshift) and 7/18 (38.9%) non-truncating mutations (6 missense and 1 in-frame deletion) were identified in individuals who developed ESRD before 60 years of age. The ESRD rate for the truncating mutations was significantly higher than that of the non-truncating ones (p = 0.023) ( Table 7) . 
Discussion
Mutation analysis of PKD1 and PKD2 in Chinese ADPKD patients has been reported previously [21] [22] [23] [24] , although with limited numbers of ADPKD families (less than 100 in all previous studies). Recently, Jin et al. [25] reported mutation analysis of PKD1 and PKD2 among 148 ADPKD patients. However, the lack of pedigree analysis in their study limited the possibility to evaluate the pathogenicity of the identified mutations, especially for those probably pathogenic mutations. In the present study, a total of 120 Chinese families with ADPKD were enrolled and 93 PKD1 and PKD2 mutations were detected. Pedigree analyses were performed for all found mutations to evaluate their pathogenicity.
In the current study, the overall detection rate of PKD mutations was 81.7%, which was consistent with the range of 52.3-85.8% reported in previous studies among Chinese populations [21] [22] [23] [24] [25] . Neither PKD1 nor PKD2 mutations were found in 22 probands with a clinical manifestation of ADPKD. A similar phenomenon was also reported in previous studies [22, 25] . Although no PKD mutations were found in these patients, the protein levels of PC1 and PC2 were probably down-regulated by other mechanisms. Previous studies had reported that microRNA-17 and microRNA-93 could bind directly to the 3′ UTR of the PKD genes and post-transcriptionally down-regulate their expression [26] [27] [28] [29] . In addition, Zheng et al. found that far upstream element-binding protein 1 could also bind to the 3′ UTR of PKD2 to suppress its translation [30] . These mechanisms might explain the absence of PKD mutations in some ADPKD patients.
The mutation rates of PKD1 and PKD2 in the present study were 91.4% and 8.6%, respectively; while most studies among Caucasian populations reported the proportion of PKD1 and PKD2 mutations to be approximately 85% and 15%, respectively [8] . In fact, most of the probands enrolled in this study were below 40 years of age, which might partially explain the small difference in the distribution of PKD mutations. Among these 93 mutations, 59.1% were reported for the first time, and the remaining 40.9% were recurrent mutations. The recurrence rate was higher than in previous reports, ranging from 16.7% to 30% in Caucasian populations [8, 17, 31] .
Definite pathogenic mutations accounted for 69.9% of all identified mutations in the present study, which was comparable to the results from the previously reported 45.1-66.6% in Caucasian populations [8, 17, 31] , but higher than the 27.7-52.2% reported in Asian populations [25, 32] . Among the definite pathogenic mutations, the large deletion mutation was a special one that was detected by MLPA analysis [15] . Previous studies reported that the detection rate of large deletions accounted for a maximum of 4% of all PKD1 mutations and even fewer among all PKD2 mutations [16] . In our study, 2 large deletion mutations were found in PKD1 with a detection rate of 2.4%, which was consistent with the data reported previously.
It is challenging to evaluate the pathogenicity of missense mutations with inadequate pedigree information. However, not all pedigree information needed for pathogenicity evaluation is easily available to researchers. Several prediction tools (PolyPhen-2, SIFT, and Mutation Taster) have been developed to assist the evaluation of the pathogenicity of missense mutations. Although the pathogenicity of most of the missense mutations evaluated by the prediction tools used in this study was consistent with the results of pedigree analysis, 2 mutations (PKD1 c.4984G>A and PKD1 c.7544G>C), which were demonstrated as benign mutations by the prediction tools, were identified as pathogenic mutations through pedigree analysis. A similar phenomenon was also found in several other related studies [33, 34] . Due to the nature of ADPKD as a single-gene inherited disease, segregation analysis is recommended as a gold standard to evaluate the pathogenicity of missense mutations rather than prediction tools. Additionally, a missense mutation (PKD1 c.8572G>A) was reported as a highly likely pathogenic mutation in PKDB [35] , while it was demonstrated to be a non-pathogenic mutation by pedigree analysis in our study. This may suggest additional information from different pedigrees is required to evaluate the pathogenicity of missense mutations.
The high level of allelic heterogeneity in both PKD1 and PKD2, as well as the prevalence of private mutations in ADPKD patients, suggest that there is a high frequency of de novo mutations in this disease. In our study, a total of 9 de novo mutations were found in 120 families (7.5%), which is larger than that reported in previous studies, ranging from 0.9% to 3.1% [17, 36, 37] . A complete collection of pedigree information from all of the involved families in our study may partially explain this difference.
A previous study reported that the average age of onset of ESRD for PKD1 and PKD2 mutation carriers was 54.3 and 74.0 years, respectively [7] . Consistently, we found that PKD1 mutation carriers had an earlier age of onset of ESRD than those with PKD2 mutations. Moreover, patients with truncating mutations were found to have a more severe clinical outcome than those with non-truncating mutations, which confirmed the strong correlation between mutation type and median age at ESRD onset identified in previous studies [34, 38] .
There are some limitations of our study that merit consideration. Firstly, most of the novel mutations were found only in single pedigrees, whose pathogenicity needs further verification by different pedigree data, especially for the probably pathogenic mutations. Secondly, although we collected as much pedigree information as possible, some of the novel missense and in-frame deletion mutations are still without complete pedigree information; thus, the pathogenicity of these mutations remains to be determined. Finally, although the pathogenicity of the atypical splicing mutations in our study was evaluated by pedigree analysis, it would be better to analyze their pathogenicity further using minigene splicing assays.
Conclusion
This comprehensive search for mutations in PKD1 and PKD2 using 120 Chinese ADPKD families found a total of 93 PKD1 (91.4%) and PKD2 (8.6%) mutations in 98 Chinese families with ADPKD. Among the 93 mutations, 59.1% were reported for the first time and 40.9% were found to be recurrent mutations. The increased number of known mutations will facilitate the early diagnosis and prognostic prediction of ADPKD patients and can serve as a genetic background for clinical interventions to block disease inheritance in affected families.
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